Testing strategy and scope
Define the authorized system boundary, interfaces, versions, assumptions, and objectives so the work is focused on credible device-relevant paths.
Talk to an expertMEDICAL DEVICE PENETRATION TESTING
Use authorized security testing to understand realistic attack paths, make proportionate product decisions, and build evidence that holds together.
Discuss your testing needs →
TEST THE PATHS THAT MATTER
Medical device penetration testing is most valuable when it is grounded in the product that will actually be used, maintained, connected, and supported. A test result may affect more than an engineering backlog. It can change the assessment of device risk, the evidence behind a design decision, the scope of a corrective action, the release plan, and the story a team needs to explain during a review.
Qualira helps medical-device teams plan and use authorized penetration testing in that wider context. The focus is a controlled assessment with a clear scope, meaningful evidence, and a practical route from findings to accountable action. Instead of leaving a report isolated from quality and regulatory work, the engagement connects it to the device, its intended use, the system boundary, and the records that need to remain aligned.
WHERE QUALIRA HELPS
Define the authorized system boundary, interfaces, versions, assumptions, and objectives so the work is focused on credible device-relevant paths.
Connect likely attack paths to the potential consequences for safety, essential performance, data, clinical workflow, availability, and product support.
Translate material findings into proportionate actions, ownership, verification needs, and records that support design, quality, and regulatory decisions.
Use the assessment to inform a major milestone, connected-product release, software change, supplier decision, or post-market security response.
FROM AUTHORIZED SCOPE TO A CLEAR ACTION PATH
A generic test can uncover technical issues, but a medical-device team needs more than a list of findings. It needs to understand what was actually assessed, whether the device configuration and intended environment were represented fairly, which interfaces or conditions made an attack path plausible, and what the result means for the product and its users.
Qualira begins with the system that exists. That can include the device, accessories, service interfaces, wireless connections, clinician or operator workstations, mobile applications, cloud services, update paths, third-party components, and the environments where the product is installed or maintained. The aim is not to test everything indiscriminately. It is to make the scope explicit enough that the team can understand both the value and the limits of the assessment.
That scope then needs to connect to the product’s risk story. A weakness may have a different consequence depending on whether it can affect therapy delivery, diagnostic information, alarm behavior, availability, protected data, clinical workflow, or the ability to recover the device safely. The same technical observation can call for different action depending on the affected configuration, the intended user, compensating controls, and the evidence already available.
Testing also needs a practical authorization and operating plan. The team should agree on systems that may be assessed, conditions that must remain protected, test accounts or equipment, escalation paths, handling of sensitive information, and when activity pauses for safety or operational reasons. Those decisions help testing remain controlled and give internal stakeholders confidence that the work supports the product rather than disrupting it.
Once testing is complete, the report should become a decision tool. Qualira can help the team distinguish an observation from a material device risk, decide which actions are immediate, connect corrective work to design and quality processes, define what verification is needed, and retain a record that explains the decision. This gives the organization a clearer path from a technical finding to an evidence-backed product response.
TESTING WITH THE PRODUCT IN VIEW
Penetration testing is strongest when it is planned alongside the device architecture, threat model, risk-management process, and verification strategy. A late test can still identify urgent issues, but it should not be the first time the team asks how a service port, update mechanism, wireless connection, remote feature, or third-party component could affect the product.
Qualira can support a focused assessment before a regulatory milestone, a design or software release, a connected-product launch, a customer security review, or a major change. The work can also help a team interpret an existing report that has raised questions across engineering, quality, regulatory, clinical, or leadership groups. The right output is not more paperwork. It is a clear account of what the finding means, who owns the response, and what evidence will show the action is complete.

WHAT A USEFUL ENGAGEMENT CLARIFIES
When a finding arrives, the fastest response is not always the most useful one. A strong path separates immediate containment from deeper investigation, identifies who needs to make the decision, and defines the evidence that will show the response is complete.
Record the device, interfaces, versions, configurations, assumptions, and limits of the authorized scope. That context keeps the result honest and helps the team decide what must be revisited when the product changes.
Evaluate realistic reachability and consequence in the intended environment. A finding becomes more actionable when the team can explain how it relates to safety, performance, availability, data, workflow, or serviceability.
Decide whether the response needs immediate containment, a design change, configuration control, a compensating measure, additional analysis, or a planned lifecycle action. The decision should reflect the device, not a generic severity label alone.
Connect the action to ownership, quality records, verification, residual-risk decisions, and release controls. This gives the organization a defensible record that the team did more than acknowledge the finding.
A USEFUL FIRST CONVERSATION
Which device interfaces, service paths, connected systems, and configurations should be in the authorized test scope?
What would a realistic attack path mean for the safety, performance, data, workflow, or availability of our specific device?
How should a material finding move through engineering, quality, regulatory, clinical, and leadership decisions?
Do we need a focused testing plan, help using an existing report, or senior support before a high-consequence milestone?
FREQUENTLY ASKED QUESTIONS
Medical device penetration testing is an authorized, controlled assessment of whether a realistic attack path could affect a device or the systems around it. It goes beyond identifying a technical weakness by examining the actual product configuration, the available controls, and the potential consequence for safety, performance, data, clinical workflow, or product support.
Testing should begin when the device boundary, important interfaces, and security requirements are clear enough to assess. It is useful before a major regulatory milestone or release, and should be revisited when material software, interfaces, connected services, or intended-use conditions change.
No. A vulnerability scan can identify known software or configuration issues. Penetration testing examines whether an authorized attack path is realistic in the device’s actual configuration and what the resulting impact could be. Both can be useful inputs, but neither replaces device-specific risk management.
A useful engagement defines an authorized scope, records the systems and versions assessed, explains the attack paths evaluated, documents evidence for material findings, and connects the outcome to device risk, corrective actions, verification, and the records the team needs next.
Yes. Qualira can help a team interpret a report in the context of the device, prioritize the findings that matter, connect actions to risk and quality records, plan verification, and decide what evidence needs to be ready for a regulatory, customer, or release decision.
TALK WITH QUALIRA